


下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAfuresertibCat. No.: HY-15727CAS No.: 1047644-62-1Synonyms: GSK2110183C分式: CHClFNOS分量: 427.32作靶點(diǎn): Akt作通路: PI3K/Akt/mTOR儲(chǔ)存式: -20C, protect from light, stored under nitrogen* In solvent : -80C, 6 months; -20C, 1 month (protect fro
2、mlight, stored under nitrogen)溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 40 mg/mL (93.61 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.3402 mL 11.7008 mL 23.4017 mL5 mM 0.4680 mL 2.3402 mL 4.6803 mL10 mM 0.2340 mL 1.1701 mL 2.3402 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請注意儲(chǔ)備液的保存式和期限
3、。BIOLOGICAL ACTIVITY物活性 Afuresertib種有效的 ATP 競爭性的特異性 Akt 抑制劑。IC50 & Target Akt體外研究Afuresertib exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells.Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among1/2 Master of
4、Small Molecules 您邊的抑制劑師www.MedChemEACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G1 phase. Westernblotting analysis shows that Afuresertib increases the expression of p21WAF1/CIP1 and decreases thephosphorylation of Akt substrates, including GSK-3 and FOXO family
5、 proteins. Afuresertib-induced p21expression promotes G1 phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression E2F1 and MYC, which are associated withfibroblast core serum response 1.PROTOCOLCell Assay 1 MPM ce
6、lls are seeded in 96-well plates (cell density, 2.5103 cells/well) and are incubated for 24 h at 37C.Next, the cells are incubated in a medium containing indicated concentrations of Akt inhibitors (e.g.,Afuresertib ; 50, 20, 10, 5, 2, 1, 0.5, 0.2, 0.1, and 0.01 M) for 72 h. Next, MTT solution is add
7、ed to each well,and the cells are incubated for 4 h. Finally, the cells are incubated overnight with lysis buffer (10% SDS in0.01 mol/L hydrogen chloride). Absorbance is measured at 550 nm using SpectraMAX M5spectrophotometer 1.MCE has not independently confirmed the accuracy of these methods. They
8、are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Cell Syst. 2018 Apr 25;6(4):424-443.e7. Int J Cancer. 2019 Aug 7. J Physiol. 2017 Jul 1;595(13):4207-4225.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Yamaji M, et al. Novel ATP-competitive Akt inhibitor Afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.Cancer Med. 2017 Nov;6(11):2646-2659.McePdfHeightCaution: Product has not been fully validated for medical applicat
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 消防安全合同管理規(guī)定
- 船舶制造材料供應(yīng)合同
- 新建住宅買賣合同備案流程
- 股權(quán)轉(zhuǎn)讓合同及相關(guān)權(quán)益轉(zhuǎn)讓協(xié)議
- 股權(quán)轉(zhuǎn)讓居間服務(wù)合同樣本
- 商鋪?zhàn)赓U合同參考模板
- 小班安全玩滑梯課件
- 創(chuàng)業(yè)企業(yè)的股權(quán)結(jié)構(gòu)設(shè)計(jì)考核試卷
- 方便食品的包裝設(shè)計(jì)與人機(jī)工程考核試卷
- 新材料新技術(shù)的巨大潛力探索未知的研究領(lǐng)域考核試卷
- 《水利工程質(zhì)量檢測管理規(guī)定》知識(shí)培訓(xùn)
- 2025年02月貴州省司法廳所屬事業(yè)單位公開招聘2人筆試歷年典型考題(歷年真題考點(diǎn))解題思路附帶答案詳解
- 2025年校長春季開學(xué)思政第一課講話稿1720字例文【供參考】
- 2025至2030年中國單板電磁制動(dòng)器數(shù)據(jù)監(jiān)測研究報(bào)告
- 2024年07月國新國證期貨有限責(zé)任公司(海南)2024年招考2名工作人員筆試歷年參考題庫附帶答案詳解
- 人教版數(shù)學(xué)八年級下冊 第17章 勾股定理 單元測試(含答案)
- 國網(wǎng)標(biāo)書制作流程
- 六年級語文教學(xué)學(xué)情分析提高六語文質(zhì)量的措施
- 中醫(yī)藥臨床適宜技術(shù)
- 銀發(fā)經(jīng)濟(jì)的發(fā)展路徑
- 工業(yè)廠房水電安裝施工方案
評論
0/150
提交評論